WO2010011117A3 - Ndga-containing composition for the suppression of transglutaminase - Google Patents
Ndga-containing composition for the suppression of transglutaminase Download PDFInfo
- Publication number
- WO2010011117A3 WO2010011117A3 PCT/KR2009/004175 KR2009004175W WO2010011117A3 WO 2010011117 A3 WO2010011117 A3 WO 2010011117A3 KR 2009004175 W KR2009004175 W KR 2009004175W WO 2010011117 A3 WO2010011117 A3 WO 2010011117A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diseases
- transglutaminase
- ndga
- present
- relates
- Prior art date
Links
- 108060008539 Transglutaminase Proteins 0.000 title abstract 6
- 102000003601 transglutaminase Human genes 0.000 title abstract 6
- 230000001629 suppression Effects 0.000 title 1
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 4
- 208000012902 Nervous system disease Diseases 0.000 abstract 2
- 208000025966 Neurological disease Diseases 0.000 abstract 2
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 229960003951 masoprocol Drugs 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to a novel use of nordihydroguaiaretic acid (NDGA) for suppressing transglutaminase activity. More specifically, the present invention relates to a pharmaceutical composition which contains NDGA as an active ingredient and which is used for the prevention or treatment of neurological diseases, inflammatory diseases and cancerous diseases which are medical conditions induced by increased transglutaminase activity. Further, the present invention relates to a method for preventing or treating neurological diseases, inflammatory diseases and cancerous diseases, which are induced by increased transglutaminase activity, by the administration of the pharmaceutical composition. The novel method of the present invention for suppressing transglutaminase by using NDGA is advantageous in that it can be applied safely and without side effects in subjects having diseases involving the abnormal expression of transglutaminase, and can effectively treat or prevent such diseases.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2008-0072912 | 2008-07-25 | ||
KR20080072912 | 2008-07-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010011117A2 WO2010011117A2 (en) | 2010-01-28 |
WO2010011117A3 true WO2010011117A3 (en) | 2010-03-25 |
Family
ID=41570759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2009/004175 WO2010011117A2 (en) | 2008-07-25 | 2009-07-27 | Ndga-containing composition for the suppression of transglutaminase |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20100011963A (en) |
WO (1) | WO2010011117A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107449848A (en) * | 2017-09-22 | 2017-12-08 | 完美(中国)有限公司 | A kind of method of La Ruia extracts in discriminating cosmetic material |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5008294A (en) * | 1985-02-11 | 1991-04-16 | Chemex Pharmaceuticals, Inc. | Methods of treating tumors with compositions of catecholic butanes |
US6214874B1 (en) * | 1999-10-15 | 2001-04-10 | John Hopkins University | Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N |
WO2003103583A2 (en) * | 2002-06-10 | 2003-12-18 | Oklahoma Medical Research Foundation | A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system |
US20060141029A1 (en) * | 2003-05-20 | 2006-06-29 | Erimos Pharmaceuticals Llc | Methods and compositions for delivery of catecholic butanes for treatment of diseases |
WO2008042921A2 (en) * | 2006-10-02 | 2008-04-10 | Erimos Pharmaceuticals Llc | Tetra-o-substituted butane-bridge modified ndga derivatives, their synthesis and pharmaceutical use |
-
2009
- 2009-07-27 WO PCT/KR2009/004175 patent/WO2010011117A2/en active Application Filing
- 2009-07-27 KR KR1020090068571A patent/KR20100011963A/en not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5008294A (en) * | 1985-02-11 | 1991-04-16 | Chemex Pharmaceuticals, Inc. | Methods of treating tumors with compositions of catecholic butanes |
US6214874B1 (en) * | 1999-10-15 | 2001-04-10 | John Hopkins University | Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N |
WO2003103583A2 (en) * | 2002-06-10 | 2003-12-18 | Oklahoma Medical Research Foundation | A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system |
US20060141029A1 (en) * | 2003-05-20 | 2006-06-29 | Erimos Pharmaceuticals Llc | Methods and compositions for delivery of catecholic butanes for treatment of diseases |
WO2008042921A2 (en) * | 2006-10-02 | 2008-04-10 | Erimos Pharmaceuticals Llc | Tetra-o-substituted butane-bridge modified ndga derivatives, their synthesis and pharmaceutical use |
Also Published As
Publication number | Publication date |
---|---|
WO2010011117A2 (en) | 2010-01-28 |
KR20100011963A (en) | 2010-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009137465A3 (en) | Compositions for treatment or prevention of pathological cardiac remodeling and heart failure | |
WO2006098603A3 (en) | Composition comprising isoorientin for suppressing histamine | |
WO2010032140A3 (en) | Pharmaceutical compositions and related methods of delivery | |
WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
WO2010123569A3 (en) | Immunonanotherapeutics providing a th1-biased response | |
EP2331095A4 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
MX2014002459A (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof. | |
WO2013166177A3 (en) | Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation | |
MX344329B (en) | Method of treating atrial fibrillation. | |
WO2009106991A3 (en) | Pyridazine derivatives and their use as therapeutic agents in the treatment of skin disorders | |
WO2007098089A3 (en) | Treatment of hyperproliferative diseases with methotrexate n-oxide and analogs | |
AU2012286851A8 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
MY163235A (en) | Pharmaceutical preparation containing pyridylaminoacetic acid compound | |
PH12017502049A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
WO2010028173A3 (en) | Method of treating atrial fibrillation | |
WO2011116139A3 (en) | Improved pharmaceutical compositions comprising cck- 8 and methods of delivery | |
WO2008054639A3 (en) | Use of a catechin or polyphenol to treat ocular diseases and infection | |
WO2010081091A3 (en) | Therapeutic compositions for treatment of corneal disorders | |
EA201390353A1 (en) | DERIVATIVE PYRAZOLOHINOLINA | |
WO2007012947A3 (en) | Method of treating ischemia-reperfusion injury | |
WO2012050831A3 (en) | Combination treatment for dermatological conditions | |
WO2011129765A9 (en) | Synergistic interaction of at least one vitamin e component and tyrosinase inhibitors for dermatological applications | |
WO2009109654A8 (en) | 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1 | |
WO2010090494A3 (en) | Medical use of 5-benzylaminosalicylic acid derivatives or salts thereof | |
AU2001266289A1 (en) | 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09800598 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09800598 Country of ref document: EP Kind code of ref document: A2 |